WO2025219955 - SOLUBLE TCRS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/219955
Publication Date
23.10.2025
International Application No.
PCT/IB2025/054084
International Filing Date
17.04.2025
Title **
[English]
SOLUBLE TCRS AND METHODS OF USE THEREOF
[French]
TCR SOLUBLES ET LEURS MÉTHODES D'UTILISATION
Applicants **
BIONTECH SE
Inventors
SROUJI, John
LUOMA, Adrienne
DULBERGER, Charles Lefco
GRAY, Justin
BIRTEL, Matthias
KAISER, Andrew D.M.
Priority Data
63/635,216
17.04.2024
US
63/721,039
15.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 13183 | |
| EPO | Filing, Examination, Granting | 403365 | |
| Japan | Filing, Examination, Granting | 6200 | |
| South Korea | Filing, Examination, Granting | 20743 | |
| USA | Filing, Examination, Granting | 74240 |
Total:
517,731
Contact Us
Abstract[English]
The present disclosure provides a therapy with soluble T cell receptors (TCRs) and cells comprising chimeric antigen receptors (CAR) including compositions, polynucleotides encoding the compositions and methods of use thereof. The methods and compositions provided herein can be used for the treatment of cancer.[French]
La présente divulgation concerne une thérapie à base de récepteurs de lymphocytes T (TCR) solubles et des cellules comprenant des récepteurs antigéniques chimériques (CAR) y compris des compositions, des polynucléotides codant pour les compositions et leurs méthodes d'utilisation. Les méthodes et les compositions de la divulgation peuvent être utilisées pour le traitement du cancer.